FDA Diagnostic Office Bests ODE In Decision Times, And Communication
This article was originally published in The Pink Sheet Daily
Executive Summary
510(k)-route diagnostic, imaging and radiation therapy systems may, on average, be in a better position to reach the market a bit sooner than other device types, according to an independent analysis by Booz Allen Hamilton. The reason, says the consulting firm: early and frequent communications by FDA’s diagnostics office.